drugset / Trial / NCT02155205

A Thorough QT Study of Telotristat Etiprate

NCT02155205

Phase 1 Completed 48 enrolled Lexicon Pharmaceuticals
RandomizedCrossoverTriple-blindTreatment

Summary

The purpose of this study is to demonstrate that telotristat etiprate does not differ from placebo in the mean change from Baseline QT interval corrected for heart rate.

Timeline

Start
2014-05
Primary completion
2014-08
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Moxifloxacin Small molecule 400 mg
Subject Telotristat etiprate Unknown 1500 mg

Indications

No indication recorded.